Aurobindo Pharma rose 4.73% to Rs 516.70 at 9:16 IST on BSE after consolidated net profit jumped 354.8% to Rs 417.50 crore on 36.3% growth in total operating income to Rs 2140.60 crore in Q3 December 2013 over Q3 December 2012.
The Q3 result was announced after market hours on Thursday, 6 February 2014.
Meanwhile, the S&P BSE Sensex was up 113.49 points or 0.56% at 20,424.23.
On BSE, so far 1.74 lakh shares were traded in the counter as against average daily volume of 7.75 lakh shares in the past two weeks.
The stock hit a high of Rs 536 so far during the day, which is a record high for the counter. The stock hit a low of Rs 510 so far during the day.
Aurobindo Pharma's consolidated EBITDA (earnings before interest, taxation, depreciation and amortization) before forex surged 148.5% to Rs 643.80 crore in Q3 December 2013 over Q3 December 2012. EBITDA margin before forex increased to 30.1% in Q3 December 2013, from 16.5% in Q3 December 2012.
Formulation sales rose 57.5% to Rs 1436.10 crore in Q3 December 2013 over Q3 December 2012. Formulation sales constituted 65.9% of gross sales in Q3 December 2013 (58% in Q3 December 2012). API sales rose 12.8% to Rs 744.50 crore in Q3 December 2013 over Q3 December 2012. API sales constituted 34.1% of gross sales in Q3 December 2013 (42% in Q3 December 2012).
Commenting on the company's financial performance, Mr. N. Govindarajan, Managing Director, Aurobindo Pharma said, "We have had a robust quarter driven by our sustaining base business along with successful launches in US, translating into better top and bottom line. We are confident to sustain the momentum as we foray into strengthening our access into markets, products and technology platforms where we are not dominantly present as we consolidate on our existing businesses".
Aurobindo Pharma, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.
Powered by Capital Market - Live News
